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Background: Development of resistance to androgen deprivation therapy (ADT) is a major obstacle for the
management of advanced prostate cancer. Therapies with androgen receptor (AR) antagonists and androgen
withdrawal initially regress tumors but development of compensatory mechanisms including AR bypass signaling
leads to re-growth of tumors. MicroRNAs (miRNAs) are small regulatory RNAs that are involved in maintenance of
cell homeostasis but are often altered in tumor cells.
Results: In this study, we determined the association of genome wide miRNA expression (1113 unique miRNAs)
with development of resistance to ADT. We used androgen sensitive prostate cancer cells that progressed to ADT
and AR antagonist Casodex (CDX) resistance upon androgen withdrawal and treatment with CDX. Validation of
expression of a subset of 100 miRNAs led to identification of 43 miRNAs that are significantly altered during
progression of cells to treatment resistance. We also show a correlation of altered expression of 10 proteins
targeted by some of these miRNAs in these cells.
Conclusions: We conclude that dynamic alterations in miRNA expression occur early on during androgen
deprivation therapy, and androgen receptor blockade. The cumulative effect of these altered miRNA expression
profiles is the temporal modulation of multiple signaling pathways promoting survival and acquisition of resistance.
These early events are driving the transition to castration resistance and cannot be studied in already developed
CRPC cell lines or tissues. Furthermore our results can be used a prognostic marker of cancers with a potential to
be resistant to ADT.
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Prostate cancer is the most commonly diagnosed can-
cer and a leading cause of cancer related death in men
in developed countries. Because androgen is required
for normal growth and functioning of the prostate
gland and also for development of cancer androgen
deprivation therapy (ADT) has become the mainstay
for advanced prostate cancer [1]. Although most pa-
tients initially respond to ADT by showing low PSA
values, they eventually develop more aggressive castration
resistant prostate cancer (CRPC). Androgen, working
through androgen receptor (AR) triggers transcriptional* Correspondence: ratna.chakrabarti@ucf.edu
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reproduction in any medium, provided the oractivation of a variety of genes that are essential for
growth and survival of prostate epithelial cells. How-
ever, prolonged androgen blockade using steroidal or
non-steroidal inhibitors such as, cyproterone acetate,
Casodex or hydroxyl flutamide, leads to activation of
various adaptive mechanisms after initial retardation of
cell proliferation [2,3].
Development of resistance to ADT, which includes
reduction in androgen synthesis and direct antagonism
of the androgen receptors (AR), can occur as a result of
high expression and activation of AR [4]. Activation of
AR without androgen is through switching of AR to
alternative mechanism of activation. Commonly noted
mechanisms include AR gene amplification, increased
coactivator expression, selection of AR gene mutation
and sensitivity to growth factors and cytokines [5]. ARl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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androgen ablation to a level that was comparable to that
in parental cell lines or androgen dependent (AD) tu-
mors prior to castration [6]. It has been proposed that
the increased activity of AR in androgen independent
(AI) cells or in relapsed tumors in castrated xenograft
mice is mediated through ligand independent mechan-
ism [7] or through promiscuous sensitivity of AR to
other steroid hormone, growth factors or cytokines [8].
Androgen blockade therapy can accumulate mutations
causing AR to become sensitive to androgen antagonists,
which then act as agonists [2,9]. It is now accepted that
CRPC maintains functional AR signaling [10,11] but an-
drogen refractoriness is through an AR bypass or adap-
tive mechanism, which is possibly, mediated through
cytokines or other survival factors. Irrespective of the
specific phenotypes acquired by the AD prostate can-
cers, the outcome is altered expression of protein-coding
genes as a whole that are responsible for progression
and metastasis of prostate cancer. In addition, nonsteroi-
dal agents such as flutamide can alter gene expression in
AR negative prostate tumors [12]. Gene expression pro-
filing in androgen dependent and androgen independent
prostate cancers revealed an increasingly complex profile
of gene expression in prostate cancer with respect to the
status of androgen sensitivity or refractoriness [13]. How-
ever, the exact mechanism of altered gene expression in
CRPC is not clear.
The role of small noncoding microRNAs (miRNAs)
in regulation of gene expression, which is mediated by
inhibition of translation or degradation of target mRNAs is
an established phenomenon [14]. MiRNAs belong to a class
of 17–22 nucleotides, which contains a specific sequence at
the 5’ end and regulates translation through binding to
3’UTR of the mRNAs [14]. To date, there are 1921 distinct
human miRNAs have been identified, each of which regu-
late multiple target mRNAs (www.mirbase.org Nov 2011).
Genes encoding miRNAs are located in the intergenic
regions or within the protein-coding genes either alone
or in clusters [15]. There is now abundant evidence that
aberrant expression of miRNAs occurs in diverse types
of cancer including prostate cancer and during different
stages of disease progression [16,17]. The role of miR-
NAs in regulation of post-transcriptional gene expres-
sion has been implicated in 30% of the protein-coding
genes [18]. Because miRNAs can be overexpressed or
down regulated in cancer cells these noncoding RNAs
are designated as oncogenic miRNAs or suppressor
miRNAs. Functionally, miRNAs reduce the levels of
many of their target mRNAs and the amount of pro-
teins encoded by these mRNAs [19]. Because a given
miRNA may have many mRNA targets the biological
effects of changes in miRNA expression is likely to be
dependent on the cellular environment.A number of studies indicated aberrant expression of
miRNAs in CRPC compared to AD prostate cancer cells
[20,21]. Several miRNAs, such as miR-21, miR-125 and
miR-32 are directly regulated by androgens in cells and
xenograft models [20,22,23]. Studies include comparative
analysis between androgen sensitive (AS) and -resistant
prostate cancer cells, with or without treatment of AS
cells with androgens or normal vs. hormone refractory
prostate cancer tissues, which only provides steady state
status of miRNA and gene expression. However none of
these studies provide information on the mechanism of
transition of androgen-sensitive or dependent prostate
cancer cells to antiandrogen resistant cells. In this study,
we show, for the first time alteration in expression of
miRNAs and their target proteins as the cells progress
to antiandrogen resistance, some of which are not de-
tectable in the established AI cell line.
Results
MicroRNA expression profile differentiates between
untreated LNCaP cells and cells treated with Casodex or
subjected to androgen withdrawal:
We used genome-wide miRNA array (1113 unique primers)
profiling approach to identify specific miRNAs that are
involved in development of resistance to Casodex (CDX).
A clonal subline of LNCaP cells LNCaP-104S (−104S)
and its androgen-independent derivative LNCaP-104R1
(−104R1) were used for monitoring differential expression
of miRNAs upon treatment with CDX. LNCaP-104S cells
are CDX-sensitive, whereas LNCaP-104R1 cells are not
despite expressing AR at a basal level higher than LNCaP-
104S cells [24]. LNCaP-104S cells require DHT for main-
taining their AD status but when treated with CDX for
3 weeks in CS-FBS (charcoal-stripped FBS), CDX insensi-
tive colonies develop that are independent of androgen
(CDXR). During the first week of both CS-FBS and CDX
treatments, LNCaP-104S cells grew without significant
cell death, however, during the second week of CDX treat-
ment about 60% cells died and detached. From the residual
40% cells, half of the cell population remained viable during
the third week of CDX treatment. CS-FBS -treated cells did
not show as much cell death during the second week of
treatment and started to regrow during the third week of
treatment. Cell morphology also changed as they are treated
with CDX and CS-FBS (Additional file 1: Figure S1). Cells
viable after third week of treatments were used for
miRNA profiling experiments. Expression of AR in these
cells showed gradual reduction as the treatment pro-
gresses, but the PSA expression increased, which sug-
gests increased transcriptional activity of the residual
AR in the treated cells (Figure 1).
We compared miRNA expressions in RNA extracts
from untreated and CDX treated -104S cells at 0 hr, 1wk
and 3wks and untreated -104R1 cells (Table 1). Hierarchical
Figure 1 Expression of AR and PSA in LNCaP cells. Western blot analysis of AR (A) and PSA (B) in LNCaP cells treated with CS-FBS and CDX
for different times. Upper panels: Total cell extracts were used for analysis of AR and PSA expression using anti-AR and -PSA antibodies. Lower
panels: Densitometric analysis of relative expression of AR and PSA in LNCaP cells. Data represents mean ± SD of three independent experiments.
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sion data (Additional file 2: Table S1) showed 5 distinct
clusters of miRNAs (Additional file 3: Figure S2). Compara-
tive analysis between samples from different conditions
using two samples Welch t-test with Log10 transformed
data and p values of 0.05 showed significant miRNAs that
are differentially expressed between conditions (Additional
file 4: Table S2 and Additional file 5: Figure S3). Volcano
plot (V plots) of the t-test between LNCaP-104S cells and
all other samples showed 38 significant miRNAs, of which
27 miRNAs were up regulated and 11 down regulated com-
pared to -104S (Additional file 5: Figure S3A). Comparison
between untreated -104S and -104R1 cells showed 24 sig-
nificant miRNAs, which includes 16 down regulated and 8
up regulated miRNAs in -104R1 (Additional file 5: Figure
S3B). Differential expression of 17 significant miRNAs was
observed between untreated LNCaP-104S cells and -104S
cells treated with CDX, of which 13 were up regulated and
4 were down regulated CDX treated cells (Additional file 5:Table 1 Cell lines and treatments
Samples
Cell line Treatment Time
point
Reference 0 hr LNCaP-104S FBS-DHT 1nM 0 hr
1wk CSFBS LNCaP-104S CSFBS 1 wk
3wks CSFBS LNCaP-104S CSFBS 3 wks
1wk CDX LNCaP-104S CSFBS/5 μM CDX 1 wk
3wks CDX LNCaP-104S CSFBS/5 μM CDX 3 wks
Test/Reference 0 hr LNCaP-104R1 CSFBS 0 wksFigure S3C). LNCaP-104S and -104S cells treated with
CSFBS also showed 9 up regulated and 5 down regulated
microRNAs in CSFBS treated cells (Additional file 5: Figure
S3D). Although -104R1 cells are CDX resistant there are
differences in miRNA expression when -104S cells were
treated with CDX (Additional file 5: Figure S3E). T-test
analysis showed 24 significant miRNAs of which 18 miR-
NAs were up regulated and 6 down regulated in -104R1
cells. Difference in miRNA expressions was also noted be-
tween -104S cells maintained in androgen-depleted condi-
tion and AI -104R1 cells. Twenty-four significant miRNAs
were identified of which 12 were up regulated and 12 down
regulated in -104R1 cells (Additional file 5: Figure S3F).
Comparison between androgen depletion and CDX treat-
ment showed 5 significant miRNAs, 4 of which were up
regulated and one down regulated in CDX treated cells
(Additional file 5: Figure S3G).
Clustering analyses using log2 transformed fold change
(FC) values of four treatment conditions compared to
-104S untreated cells showed two distinct clusters of up
and down regulated miRNAs, which includes 307 down
regulated and 197 up regulated miRNAs (Figure 2 and
Additional file 6: Table S3). K-median clustering for the
up-regulated miRNAs showed a trend of gradual in-
crease in median FC in miRNAs in some clusters (clus-
ter 1, 4 and 9) and a gradual decrease in some clusters
(clusters 3, 7 and 8) from 1 week to 3 weeks treatments
(Figure 3A and Additional file 7: Table S4). In down reg-
ulated profile there is also a trend of gradual decrease in
median expression of miRNAs in some clusters (clusters
1, 2, 3 and 7) (Figure 3B and Additional file 7: Table S4).
Of these lists, 100 miRNAs were chosen based on fold
Figure 2 Cluster analysis of fold change in expression of miRNAs in different treatment conditions. Hierarchical clustering of log2
transformed FC expression of miRNA in four treatment groups, 1wk CSFBS, 1wk CDX, 3wks CSFBS and 3wks CDX (Table 1). Red line and green
lines showing the expression patterns of 197 up regulated and 307 down regulated miRNAs (Supplemental data 3), respectively.
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Figure 3 K-median cluster analysis for differentially expressed miRNAs at different treatment conditions and time points. A) Up regulated
miRNAs separated into 10 clusters based on similar trends in expression patterns are depicted. MiRNAs in each cluster are showing a unique pattern of
expression among 1wk and 3wks treatments of both CDX and CSFBS. B) Down regulated miRNAs divided into 10 clusters based on similar trends in
expression are shown. MiRNAs in each cluster are showing unique patterns of expression during 1wk and 3wks treatments of CDX and CSFBS. Data
shows median ± SD of expression of miRNAs in each cluster.
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using qPCR.
Validated expression of miRNAs revealed distinct differences
in expression in different treatment conditions
Analysis of qPCR data indicated a variable expression pro-
file of a subset of miRNAs in LNCaP cells exposed to CDX
and/or androgen withdrawal (CSFBS) for different time pe-
riods. Two sample Welch t-test with a p-value < 0.05
showed a significant change in expression of 21 miRNAs in
treated samples compared to the untreated -104S cells (Fig-
ure 4A and Additional file 8: Table S5). Comparison be-
tween -104S untreated and either CDX or CSFBS treated
samples identified 10 and 8 significant miRNAs respectively
(Figure 4A) Comparative expression analysis between CDX
1wk and CDX 3wks also revealed significant change in ex-
pression in 3 miRNAs (Figure 4A). Venn Diagram ofmiRNA expression profiles following CDX treatment and
androgen withdrawal indicated two common miRNAs
(miR-146a and miR-759) but treatment specific differential
expression was observed with 8 and 6 unique miRNAs, in
CDX and CSFBS treated respectively (Figure 4B). Analysis
of the up-regulated miRNAs revealed 10 miRNAs that
showed 2-fold or higher expressions in all treatment condi-
tions and time points (Figure 4C). There are also 30 miR-
NAs that showed 2-fold or higher expression in more than
one treatment conditions. In the down regulated list, 9
miRNAs showed at least 2-fold reduction in expression in
all treatment conditions and 15 miRNAs with ≥2.0-fold
down regulation in more than one treatment conditions
(Figure 4D).
Cluster analysis of log2 transformed FC in expression
of 100 miRNAs showed three distinct clusters displaying
common expression changes in 2 time points of two
Figure 4 Comparative analysis of the expression of validated miRNAs during progression to ADT and CDX resistance. A) Volcano plots
depicting significant miRNAs identified by two sample t-test in all treatment conditions compared to untreated -104S cells (1st panel from left), in
all CDX treated cells compared to untreated S cells (2nd panel from left), in 3wks CDX treated cells compared to 1wk CDX treated S cells
(3rd panel from left) and in all CSFBS treated cells compared to untreated S cells (4th panel from the left). B) Venn diagram using significant
miRNAs identified in two sample t-tests (volcano plots) showing common and unique miRNAs between all -104S CSFBS and -104S CDX treated
cells. C: List of common up-regulated miRNAs as noted in Venn diagram in all treatment conditions, between 1wk CDX and 3wks CDX and
between 3wks CDX and 3wks CSFBS cells. D. List of down regulated miRNAs in all treatment conditions, between 1wk CDX and 3wks CDX and
between 3wks CDX and 3wks CSFBS cells.
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with increased expression and one cluster containing
down regulated miRNAs (Figure 5A and Additional file
9: Table S6). K-median clustering of the up-regulated
miRNAs showed a distinct trend of gradual increase
(clusters 1 [32%], 2 [26%] and 4[11%]) and gradual de-
crease (cluster 3 14%) in FC expressions as the treatment
progressed (Figure 5B and Additional file 10: Table S7).
Some of the miRNAs (21) showed across the board up
regulations (Table 2). Similarly, in the list of down-regu-
lated miRNAs a gradual decrease in expression (clusters
1[18%] and 2 [21%]) could be noted as the treatment
progressed (Figure 5C) and a subset of miRNAs (22)
showed down-regulation in all treatment conditions
(Table 3). When compared with published expression
database there are supporting reports on expression pat-
terns of specific miRNAs in different types of cancer(Tables 2 and 3). There are also opposing reports on ex-
pression of miRNAs, which includes, miR-106a [25],
miR-15b [26], miR-17 [27], miR-18 [28], miR-205 [29],
miR-20 [30] and miR-7 [31] for down regulated miR-
NAs; and let-7f-1 [32], miR-136a [33], miR-143 [34],
miR-146a [35], miR-218 [36], miR-22 [37], miR-222 [38]
miR-29a [39], miR-34b [40], and miR-493 [41] for up-
regulated miRNAs.
Involvement of miRNAs in specific cellular processes
which differ between treatment conditions
MicroRNAs exhibiting up regulation or down regulation
in all treatment conditions compared to untreated -104S
cells (Tables 2 and 3), were used for function and disease
relevance to understand the possible alterations in the
ellular processes as LNCaP cells progressed towards an-
drogen withdrawal and AR antagonist resistance. We
Figure 5 Cluster analysis of fold change in expression of validated miRNAs in different treatment conditions. A) Hierarchical clustering of
log2 transformed FC expression of miRNA in four treatment groups, 1wk CSFBS, 1wk CDX, 3wks CSFBS and 3wks CDX (Table 1). Red arrows and
green arrows showing the expression patterns of 21 up regulated and 22 down regulated miRNAs (Tables 2 and 3), respectively. B, C) K-median
cluster analysis of the validated miRNAs in different treatment conditions B) Up-regulated miRNAs are divided into 5 clusters, which show unique
trends of expressions. All miRNAs in each cluster show similar trends in expression in all treatment conditions and time points. C) Down regulated
miRNAS are divided into 7 clusters each showing unique trend of expression pattern of miRNAs. All miRNAs in each cluster is showing similar
patterns of expression. Data shows median ± SD of expression of miRNAs in each cluster.
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lated miRNA for the analysis using IPA software (Ingenuity
Systems). Based on -log (p-values) with -values <0.05, a per-
centage of miRNAs were assigned to certain disorder or
cellular processes (Additional file 11: Figure S4). When the
functional profiles of the p-regulated miRNAs were com-
pared, there is a decrease in the percentage of miRNAs in-
volved in cancer, dermatological disease, and hematological
disease between 3wks and 1wk CDX treated cells whereas
an increase in the percentage of miRNAs involved in endo-
crine system disease, gastrointestinal disease hepatic system
disease, reproductive system disease and metabolic disease
in 3wks CDX treated S cells compared to 1wk CDX treated
cells (Additional file 11: Figure S4A). In cells subjected to
androgen withdrawal, there are also differences in percent-
age of miRNAs in different cellular processes between 1wkand 3wks treatments, which show a reduction in
hematological diseases, cellular development, and repro-
ductive system disease. An increased involvement of miR-
NAs in a variety of cellular processes also was noted in 3wk
CSFBS treated cells, which includes cell death and survival,
cell movement, endocrine system disease, gastrointestinal
disease, hematological disease, hepatic system disease and
metabolic disease (Additional file 11: Figure S4A).
In the list of down-regulated miRNAs, there is an
increase in percentage of miRNAs involved in cell
morphology, cell movement, dermatological disease,
gastrointestinal disease, renal urological disease, and re-
productive system disease as cells progressed from 1wk
to 3wks CDX treatment. A decreased percentage of
down regulated miRNAs in specific cellular processes
also could be noted in these cells, which includes












hsa-let-7f-1 12.50 12.17 13.91 17.64 [42,43]
hsa-miR-136 3.69 3.44 5.16 4.30 [44,45]
hsa-miR-143 15.80 19.67 13.92 6.25 [46,47]
hsa-miR-146a 31.44 20.83 56.46 50.68 [48,49]
hsa-miR-218 4.64 2.33 18.44 11.49 [50,51]
hsa-miR-22 2.39 2.43 4.58 3.10 [52]
hsa-miR-22* 15.91 11.56 11.78 22.47 NA
hsa-miR-222 3.65 1.99 7.05 4.63 [53,54]
hsa-miR-29a 2.09 1.58 4.60 4.24 [55,56]
hsa-miR-302a* 2.97 7.73 3.87 4.48 [57,58]
hsa-miR-3138 6.53 5.94 6.66 5.96 - NA
hsa-miR-3144b-5p 11.25 4.39 4.47 8.53 [59]
hsa-miR-3192 8.70 2.11 5.52 5.71 - NA
hsa-miR-3199 1.25 4.54 2.71 6.76 - NA
hsa-miR-34b* 3.15 2.34 6.69 8.64 [60,61]
hsa-miR-493* 1.31 1.42 2.31 15.06 [62]
hsa-miR-548h 2.12 3.76 4.06 6.72 - NA
hsa-miR-548l 3.94 3.11 8.66 7.40 - NA
hsa-miR-548p 3.88 2.44 4.64 1.55 - NA
hsa-miR-548t 4.89 9.65 1.26 5.46 - NA
hsa-miR-664 3.81 4.01 5.16 5.05 [63]
NA: Not available. *denotes the star strand, which is currently designated as -3p or -5p. Thickness of arrows represents number of publications available
corresponding to the expression pattern.
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system disease, tumor morphology and inflammatory re-
sponse. Androgen withdrawal for 1wk to 3wks also
showed changes in percentage of miRNA involvement
(Additional file 11: Figure S4B). An increased percentage
of down regulated miRNAs involved in cancer, cell death
and survival, dermatological disease, endocrine systemdisease, gastrointestinal disease, metabolic disease, and
tumor morphology is noted in 3wks CSFBS treated cells.
3wks androgen withdrawal also showed a decrease in
miRNA percentage involved in cell growth and prolifera-
tion, cell movement, cell-cell signaling, DNA replication
and repair and renal-urological disease (Additional file 11:
Figure S4B).












hsa-miR-106a −2.37 −3.18 −5.29 −9.40 [64,65]
hsa-miR-1244 −3.40 −8.55 −5.14 −3.38 - NA
hsa-miR-15b −1.86 −2.02 −2.85 −3.33 [66,67]
hsa-miR-15b* −2.42 −4.65 −3.83 −9.76 [68,69]
hsa-miR-17 −2.91 −3.37 −2.50 −24.99 [70,71]
hsa-miR-17* −3.15 −3.13 −5.26 −3.94 [68,72]
hsa-miR-18a −2.01 −4.36 −14.70 −14.13 - [73]
hsa-miR-18b −1.56 −2.28 −4.92 −21.36 [74,75]
hsa-miR-205 −6.33 −12.51 −12.06 3.89 [76,77]
hsa-miR-205* −0.35 −1.34 −2.85 −3.23 - NA
hsa-miR-20a −2.73 −3.31 −3.78 −4.12 [71,75,78]
hsa-miR-20a* −1.78 −1.25 −2.64 −18.17 - [69,75]
hsa-miR-20b* −0.64 −0.56 −7.99 −4.60 - [74,75,79]
hsa-miR-3131 −2.35 −2.97 −3.14 −3.41 - [80]
hsa-miR-3185 −2.95 −3.24 −4.17 −5.76 - [80]
hsa-miR-422a −3.15 −3.15 −4.92 −6.87 - [81]
hsa-miR-454 −0.58 −1.89 −3.28 −3.76 [75,82]
hsa-miR-518b −2.64 −6.42 −5.61 −12.23 - [83]
hsa-miR-596 −2.45 −3.94 −15.83 −12.71 - [84]
hsa-miR-759 −13.05 −10.92 −6.17 −5.86 [82]
hsa-miR-7 −3.00 −5.23 −6.76 −11.08 - [85]
hsa-miR-9 −2.64 −4.35 −4.53 −3.55 [86]
NA: Not available, *denotes the star strand, which is currently designated as -3p or -5p. Thickness of arrows represents number of publications available
corresponding to the expression pattern.
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different treatment conditions indicated a complex inter-
action of a network of miRNAs and their target proteins
in these cells which rendered them adaptive to the an-
drogen withdrawal and treatments with AR antagonists.
Next, we analyzed the network of interactions among
target miRNAs. We used the log2 transformed FC values
of the subset of validated miRNA (Tables 2 and 3) for
analysis of the functional interrelationship amongmiRNAs (Figure 6). The network for up-regulated miR-
NAs and its putative targets in 3wks CDX showed that
miR-3192 directly and miR-218 indirectly through
DEAD box protein DDX20 target p53. MiR-146a also
directly regulates a number of Toll-like receptors (TLR1,
TLR9 and TLR10), cytokine receptors and its associated
proteins (IL1R1, IL12RB2, IL1RAP) and chemokine re-
ceptors (CXCR4, CCR3) (Figure 6A). In addition, miR-
146a directly targets a number of growth factors and
Figure 6 Analysis of miRNA-regulated network of interacting partners involved various signaling pathways. A) Log2 transformed FC
values of 21 up regulated miRNAs were imported into the Core analysis tool of IPA software and a network for interacting miRNAs and their
direct target proteins and proteins that target any of the up regulated miRNAs has been generated for 3wks CDX treated cells. Red symbols
denote miRNAs or mature miRNAs. Proteins include growth factor/cytokines, enzymes, kinases, phosphatases, peptidases, translational regulator,
transcriptional regulators, and transporters. B) The network in A is overlayed with disease relationship showing association of miRNA and protein
interactions with various types of cancer. C and D) Regulatory network of the log2 transformed FC values of 22 down regulated miRNAs and their
target proteins in 3wks CDX treated cells (C) and overlay of disease association of the miRNA-protein regulatory network (D). Green symbols
represent down regulated miRNAs and mature miRNAs. E and F) Regulatory network of log2 transformed FC values of the up regulated miRNAs
and their target proteins in cells treated with CSFBS for 3wks (E) and an overlay of disease relationship with the regulatory network in E. Red
symbols represent miRNAs and mature miRNAs. G and H) Regulatory network of log2 transformed FC values of the down regulated miRNAs and
their target proteins in cells treated with CSFBS for 3wks (G) and an overlay of disease association with the regulatory network in G (H). Green
symbols represent down regulated miRNAs and mature miRNAs.
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shown in the up-regulated network of 3wks CSFBS, in
addition to BRCA, which is a direct target of miR-146a
(Figure 6E). MiR-3192 targeting of p53 is also noted in
3wks CSFBS but not of miR-218 (Figure 6E). As noted
in the networks, p53 also regulates a number of miR-
NAs, such as, miR-29b-3p, miR-22-3p, miR-22-5p and
miR-221-3p (Figure 6A and E). When the networks are
overlaid with diseases, a number of miRNAs in the up-
regulated list of both 3wks CDX and 3wks CSFBS
showed involvement in a variety of cancers includingpancreatic cancer, endocrine gland tumor, prostate can-
cer, ovarian tumor, mammary tumor, cervical cancer and
epithelial neoplasia (Figure 6B and F).
In the list of down-regulated miRNAs there is direct tar-
geting of E2F2, E2F3, MAP3K12, FXR1 and AR interacting
nuclear protein kinase HIPK3 by miR-17-5p. MiR-16p also
directly targets BCL2L2, cell death suppressor BNIP2,
EGFR, RAB21 and single strand purine rich DNA binding
protein PURA (Figure 6C and G) in both 3wks CDX and
3wks CSFBS treated cells. Also a number of miRNAs in the
down regulated list down regulate a number of common
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http://www.molecular-cancer.com/content/13/1/1targets, such as E2F3 is targeted by miR-1244, miR-596,
miR-18a-5p, miR-16-5p and miR-17-5p. EGFR is also tar-
geted by miR-7a-5p and miR-16-5p. Overlay of diseases on
networks revealed a distinct association of miR-17-5p, with
various cancers including prostate cancer, breast cancer
and pancreatic cancer and endocrine gland tumors. An as-
sociation of miR-16-5p with prostate cancer, pancreatic
cancer, pituitary cancer and endometrial cancer also could
be noted (Figure 6D and H). These networks indicate a
complex interplay of microRNAs and proteins during de-
velopment of resistance of LNCaP cells to androgen with-
drawal and treatment with CDX.
Target identification of the subset of miRNAs revealed
potential activation and/or inactivation of a number of
proteins involved in different signaling networks
A total of 21 up regulated and 22 down regulated miRNAs
in all treatment conditions were used for identification of
protein targets using IPA, miRDB and TargetScan software.
Venn diagram of the putative targets of up-regulated miR-
NAs derived from the network generated using the IPA
software showed 27 proteins that are common in all treat-
ment conditions (Figure 7A). A number of which are
known tumor suppressors such as BRCA1[87], TP53 88],
RAD54L [89], IRF5 [90], DUSP2 [91], IKK1 or CHUK [92].
Other targets of up regulated miRNAs in different
treatment conditions also includes proteins that inhibit
tumor progression, such as DNMT3A [93], FADD [94],
pTEN [95], FOXO3[96], DDX20 [97] and PA2G4 (EBP1)Figure 7 Analysis of treatment specific targets regulated by validated
potentially regulated by miRNAs that are up regulated in different treatmen
network generated by IPA software. B) Venn diagram depicting predicted
conditions. Targets were identified based on the regulatory network using[98]. There are also 41 common targets of the down-
regulated miRNAs in all treatment conditions (Figure 7B).
Some of the targets are known oncoproteins, which in-
cludes EGFR [99], VEGFA [100], ZBTB7 (POKEMON)
[101], acid phosphatase 2(ACP2) [102] and NFKB1 [103].
Additionally, proteins that are overexpressed in cancer cells
are among the targets of down-regulated miRNAs in differ-
ent treatment conditions, which includes Wnt3A [104],
PPARα [105], UCP2 [106], CSF1 [107], and MED1 [108].
Targets of miRNAs showed the predicted expression
profiles in LNCaP cells subjected to androgen withdrawal
and CDX treatment
Further identification of the targets of selected miRNA
(Table 2) was conducted by miRDB and TargetScan data-
base search and proteins that are regulated by one or mul-
tiple miRNAs from our list and received higher target
scores in either or both searches are presented in Tables 4
and 5. The selected proteins that are regulated by the up-
regulated miRNAs include TNF receptor associated factor
6 (TRAF6) [109], interleukin receptor associated kinase1
(IRAK1), BCL6 co-repressor-like 1(BCORL1) [110], Cbl
[109], neuro oncological ventral antigen1 (NOVA1) [111],
coiled coil domain containing 67 (CCDC67) [112] NET1
[113], ZFAND1(Acc.# NM_024699), RGS6 [114] CDKN1B
(p27Kip1) [115], IGFBP5 [116] and RNASEL [117]
(Table 4). The proteins that are potentially regulated by
the down-regulated miRNAs include, ABHD3 [118],
FGD4 [119], CCNJ [120], CHAMP1 [121], Myb [122],miRNAs. A) Venn diagram showing specific targets that are
t conditions. Putative targets were identified based on the regulatory
targets regulated by the down-regulated miRNAs in different treatment
IPA software.
Table 4 Predicted mRNA Targets of Up-Regulated miRNAs




TRAF6 TNF receptor-associated factor 6, E3 ubiquitin
protein ligase
miR-146a 100 94,94,65,50,38,19
IRAK1 Interleukin receptor associated kinase 1 miR-146a 87 98
BCORL1 BCL6 corepressor-like 1 miR-146a, miR-143, miR-548t 77,68 98,80
NOVA-1 Neuro-oncological ventral antigen1 miR-146a, miR-143, miR-548l 97,93,86 97,89,87
CCDC67 Coiled-coil domain containing 67 miR-22 77 99,97
Cbl Cbl proto-oncogene, E3 ubiquitin protein ligase miR-22, miR-222,miR-136, miR-3199,miR-1197 87,83,64,55 86,84,75,61,43,33,32,31
NET1 Neuroepithelial cell transforming 1 miR-22, miR-222,miR-143 93,61 98
ZFAND1 Zinc finger, AN1-type domain 1 miR-548h, miR-548l,has-miR-548t,miR-136 96,70 93,83,99,52
RGS6 Regulator of G-protein signaling 6 miR-222 75 91,96,12
CDKN1B Cyclin-dependent kinase inhibitor 1B (p27, Kip1) miR-222 85 93,95
IGFBP5 Insulin-like growth factor binding protein 5 miR-143 N/A 99
RNASEL Ribonuclease L miR-146a, miR-548l 74 81
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[125], EGFR [126], E2F1 [127] and DOK4 [128]. West-
ern blot analysis confirmed the predicted expression
profiles of some of the targets. Expression of Cbl,
p27Kip1, TRAF6, IRAK1, and ZFAND1 were significantly
and progressively down regulated in cells treated with
CDX or subjected to androgen deprivation (Figure 8).
Similarly, expression of FGD4, VEGFA, EGFR, DOK4
and ABHD3 were up regulated to moderate to high
levels in cells treated with CDX or CSFBS (Figure 9).
Discussion
Our studies on profiling and validation of miRNA expres-
sions during transition of AD LNCaP-104S cells to AI andTable 5 Predicted mRNA Targets of Down-Regulated miRNAs
GeneID Gene Description
ABHD3 Abhydrolase domain containing 3 miR-12
CCNJ Cyclin J
CHAMP1/ZNF828 Chromosome alignment maintaining
phosphoprotein 1
miR





VEGFA Vascular endothelial growth factor A m
FGD4 RhoGEF and PH domain containing 4 miR-1
SPOPL Speckle-type POZ protein-like
RAB9B RAB9B, member RAS oncogene family miR-15b-5p, mi
EGFR Epidermal growth factor receptor
E2F1 E2F transcription factor 1 miR-2
DOK4/IRS-5 Docking protein 4CDX resistant cells revealed activation and inactivation of
several signaling networks. We noted a difference in
miRNA expressions between the AI subline LNCaP-
104R1, and freshly generated CDX resistant LNCaP-104S
cells, which includes some of the up regulated (miR-146a)
and down-regulated miRNAs (miR-15b-3p and miR-18b).
Although we noted differential expression of miRNAs be-
tween CS-FBS and CDX treated LNCaP cells we selected
only miRNAs that showed either up regulation or down
regulation in all treated samples for analysis of their puta-
tive targets. Despite similar expression profile of specific
miRNAs in CS-FBS and CDX treated samples, some the
targets such as DOK4 and VEGF showed differential ex-




44, miR-130a, miR-205 74, > 85 84
miR-205-5p 90 98
-7-5p, miR-378a-3p 60-96 96
-15b-5p, miR-16-5p 74 96
miR-7-5p 94 91
iR-205, miR-15b 79 97
7, miR-106a, miR-20a 100 98
miR-9-3p 97 97
R-16-5p, miR-130a-3P, miR-9-5p 67-86 67-86
miR-7 81 93
05, miR-17, miR-20b 77 80
miR-205 N/A 94
Figure 8 Comparative analysis of target protein expression in LNCaP sublines in different treatment conditions. Western blot analysis of
the target proteins identified using TargetScan and miRDB online prediction tools for a particular miRNA (shown in Table 2). Total proteins
from -104S cells untreated and treated for different times, and -104R1 cells untreated were used for immunoblotting using anti-cbl (A), -p21Kip1
(B), -TRAF6 (C), -ZFAND1 (D) and –IRAK1 (E) antibodies. Upper panel shows representative images of the western blots. Bottom panel shows
densitometric analysis of relation protein expression. Data shows mean ± SD of at least three independent experiments. *p < 0.05, **p < 0.01,
significance was calculated between LNCaP-104S untreated vs. specified treated cells.
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http://www.molecular-cancer.com/content/13/1/1could be the effect of regulation of multiple targets by a
given miRNA, which may indirectly affect the net expres-
sion of DOK4 and VEGF.
Over expression of miR-146a was noted in all treated
cells contrary to the study showing loss of expression of
miR-146a in CRPC [129]. Increased miR-146a expression
was substantiated by down regulation of its two bona
fide targets TRAF6 and IRAK1 in both -104R1 and 3wks
treated -104S cells. MiR-146a expression is induced by
NF-κB [130] and acts in a negative feedback loop through
degradation of TRAF6 and IRAK1 to reduce NF-κB
signaling and inflammatory response. An increase in
transcription of miR-146a, as a result of elevated NF-κB ac-
tivity is noted in thyroid cancer [131] and down regulation
of miR-146a is associated with hyperactivation of NF-kB
[132]. Despite this association, an increase in NF-kB1
expression could be predicted in treated -104S cells, as
NF-kB1 is a direct target of the down-regulated miRNAmiR-9 [133]. Increased expression of the other subunit
RelA, which heterodimerizes with NF-kB1 also could be
predicted as it is a direct target of the down-regulated
miR-7 [134]. It appears that the NF-kB signaling pathway is
activated in the early stages of gaining resistance to CDX/
androgen blockade and the increased expression of miR-
146a is a secondary effect of the activation of the NFkB
pathway. As a result, in the initial stages of anti-androgen
drug resistance there is decreased inflammatory response
but down regulation of tumor suppressor targets of miR-
146a, BCORL1 [135] and RNASEL [136], which may not
be detected in fully developed CRPC.
The EGFR signaling pathway could be activated also
in the early stages of androgen blockade and CDX
treatment. The evidence of EGFR pathway activation
in the treated -104S cells is from our results showing
an increased expression of EGFR, down regulation of
miR-7 and up-regulation miR-222, which are the miRNA
Figure 9 Comparative analysis of target protein expression in LNCaP sublines in different treatment conditions. Western blot analysis of
predicted target proteins regulated by down regulated miRNAs (shown in Table 3). Total proteins from all treated and untreated cells were used
for immunoblot analysis using anti- FGD4 (A), ABHD3 (B), -DOK4 (C), VEGFA (D), and EGFR (E) antibodies. Upper panel shows representative
images of the western blots. Bottom panel shows densitometric analysis of relation protein expression. Data shows mean ± SD of at least three
independent experiments. *p < 0.05, **p < 0.01, significance was calculated between LNCaP-104S untreated vs. specified treated cells.
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http://www.molecular-cancer.com/content/13/1/1regulators of EGFR. Decreased expression of p27Kip1 and
Cbl, as two other targets of the up-regulated miR-222,
further aid activation of EGFR signaling. C-Cbl, an E3
ubiquitin ligase, inactivates ligand-bound EGFR through
EGFR-Cbl complex formation leading to its degradation
[137]. C-Cbl activation mediates the tumor suppressive ef-
fects of EPhB6 and inhibits cancer cell invasiveness [138].
C-Cbl is also targeted by the up regulated miRNA miR-136
in all treated cells. Down regulation of c-Cbl in treated -104S
and untreated -104R1 cells possibly promotes antiandrogen
resistance through EGFR stabilization. A loss of expression
of AR was noted in these cells (data not shown), which
supports the report showing an inverse relationship
between expression of AR and EGFR in prostate cancer
patients [139]. Up regulation of miR-136 in treated -104S
cells was substantiated by the loss of expression of the
miR-136 target ZFAND1, an uncharacterized AN1 type
zinc finger domain 1 containing protein.Activation of PI3K/AKT signaling axis also could be
predicted in treated -104S cells, as a result of down regula-
tion of miR-7, which inhibits tumor growth and metastasis
through inhibition of PI3K/AKT pathways [85,140]. Down
regulation of miR-7 in cancer cells including glioblastoma
and its inhibitory effects on EMT and metastasis is well
documented [141]. Activation of this pathway could be
further aided by over expression of MiR-22 in all treated
cells, which exerts a proto oncogenic effect through down
regulation of PTEN in AI prostate cancer cells [142]. Add-
itionally, activation of VEGF and DOK4 could be predicted,
as these proteins are over expressed in treated -104S cells
possibly as a result of down regulation of their regulatory
miRNA, miR-205. Earlier studies showed an association
between poor prognosis of localized prostate cancer and
epigenetic repression of miR-205 [77], and thus confirms
the relevance of the loss of miR-205 in development of
CDX resistance. DOK4 is a newly identified substrate
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phosphorylation translocates to mitochondria and re-
cruits c-Src kinase to the mitochondria. Up regulation
of DOK4 is also noted in renal cell carcinoma [128].
VEGFA is a target of miR-15b-5p also, which showed
2-10-fold reduction in expression in treated -104S cells and
in chemotherapy-resistant squamous cell carcinoma [67].
Other than modulation of specific signaling axis, altered
expression of miRNA clusters is also evident in our study.
Members of the miR-17-92 and its paralogous miR-
106a-363 clusters, miR-17, miR-18a, miR-18b, miR-20a
and miR-106a showed ~9-10-fold down regulation upon
CDX treatment and androgen blockade. In support of our
observation, loss of expression of miR-17 [71], miR-
18a [73], miR-20a [78] and miR-106a [65] are reported
in breast and other cancers. Loss of expression of miR-
106a, miR-17 and miR-20a are further supported by an
increased expression of their target protein FGD4 in
these cells. Contrary to the published study [143], over
expression of miR-34b was noted in AI and CDXR cells,
however, an inverse relationship between miR-34b expres-
sion and disease free survival of triple negative breast can-
cer has been reported [61], which suggests that miR-34b
expression may be dependent on the status of hormone re-
sponsiveness. Among the other up regulated miRNAs, over
expression of let-7f1 [42], miR-143 [46], miR-218 [50], miR-
29a [55], miR-302a [57], miR-3144 [59], miR-493 [62] and
miR-664 [63] in cancer cells has been reported earlier. Our
study also identified a number of miRNAs with > 2-fold
difference in expression such as miR-3138, miR-3192,
miR-3199, and a subset of miR-548 series, which are not
yet known to be involved in development of CRPC.
Additional miRNAs such as miR-518b, miR-205 and
miR-596 showed > 10-fold loss of expression upon CDX
treatment or androgen withdrawal. In support of our
observation, loss of expression and tumor suppressor
functions of mir-518b and miR-596 has been documented
in other cancers [83]. MiR-1244 and miR-759 are two other
miRNAs that are significantly down regulated in all treated
cells. This is substantiated by an increased expression of
their common target ABHD3 in these cells [118]. Among
the other down regulated miRNAs, miR-9 and miR-422a
are known to have tumor suppressor roles in various cancer
cells [81,86], whereas miRNAs −454, -3131 and −3185
are noted for the first time to be deregulated during
progression of CRPC.
Functional contribution of some of the identified
microRNAs in development of CRPC has been previously
reported. Over expression of miR-222/221 in AI LAPC4
cells was shown to promote androgen independent cell
growth, which was abrogated upon expression of anti-
miR-222/221 inhibitors [21]. Down regulation of miR-
205 has been correlated with advanced prostate cancer
and ectopic expression of miR-205 suppressed AR andMAPK signaling and inhibited cell growth [144]. Down
regulation of miR-17 in AI prostate cancer cells also
has been demonstrated. Expression of pre-miR-17 in
these cells prevented AR induced gene transcription and
inhibited cell proliferation [145].
Analysis of the altered cellular processes during progres-
sion towards CDX resistance and androgen independence
showed a decreased percentage of miRNAs involved in can-
cer but an increased percentage in reproductive system,
endocrine system, hepatic system and metabolic diseases. It
can be speculated that up regulated oncomirs at earlier
stages aid in transformation of cells through suppression of
tumor suppressors. Whereas, at later stages accumulation
of abnormal cellular events triggers expression of additional
sets of miRNA, which inhibit key regulatory proteins in-
volved in metabolic process, hormone response and other
cellular events. Our qRT-PCR FC data indicate differential
expression of miRNAs between 1wk and 3wks treatment,
which would have been undetected had the profiling been
done only in CDX sensitive/AD and –resistant/AI cells.
In silico analysis identified a number of targets that are
potentially regulated by one or more altered miRNAs.
This includes, two mitosis regulatory proteins CCNJ
and CHAMP1 (ZNF828) [120,121], two oncogenic proteins
PIK3CD [85] and MYB that are over expressed in CRPC
[122], a protein trafficking regulatory protein RAB9B, a
ubiquitination promoting protein SPOPL involved in
the Hedgehog/Gli signaling pathway [124] and E2F1
transcription factor [127].
In summary, our results and in silico network analysis
suggest that inhibition of expression of TP53, BRCA,
Toll like receptors, IRAK1, STAT1, CHUK and FADD
by the up regulated miRNAs, and increased synthesis
of EGFR, NFkB1/RelA, E2F family members, BCL2L2,
ZBTB7A, EGO2 (EIF2C2) and ZEB2 as the targets of
down regulated miRNAs are part of the events that
support growth and survival of AI LNCaP cells. During
treatment with AR antagonist in androgen-deprived condi-
tion, additional inhibition of expression of DDX20, URF1,
IRF5 and CDKN3 as the targets of the up regulated miR-
NAs and increased expression of PRDM1, DOK4, TNFSF9
and NOTCH2 as a result of down regulated miRNAs may
provide additional protection against CDX induced cell
death. In-depth studies are needed to accurately deter-
mine the activation and inactivation of specific signaling
pathways during development of insensitivities of pros-
tate cancer cells to AR antagonistic drugs.
Conclusion
The overall evaluation of the changes in expression profiles
of miRNAs during transition of CDX sensitive and AD cells
to the CDX resistant and AI ones demonstrates that
not any one or two miRNAs are responsible for develop-
ment of drug-resistant prostate cancer. Instead, a complex
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pathways aided by degradation or accumulation of the tar-
get mRNAs as a result of differential expression of a sig-
nificant number of miRNAs plays the pivotal role. Also,
there are transient changes in the expression of miRNAs
as well as their target proteins during transition of cells to-
wards ADT resistance, which may provide growth and
survival advantage to a subset of cancer cells; and these
changes in miRNA/mRNA signature may be missed in
already developed castration resistant prostate cancer.
This study provides a predictive tool for monitoring the
susceptibility of development of anti-androgen therapy
resistant prostate cancer.
Materials and methods
Cell culture, and treatments
The androgen responsive LNCaP-104S and androgen
independent LNCaP-104R1 cells were generous gifts
from Dr. Shutsung Liao, University of Chicago. These
LNCaP sublines were isolated and characterized as previ-
ously described [146]. LNCaP-104S cells were maintained in
DMEM (Gibco) containing 10% FBS (Atlanta Biologicals),
1nM DHT (Sigma-Aldrich), 1% Antibiotic/Antimycotic
(Invitrogen). LNCaP-104R1 cells were maintained in
DMEM containing 10% charcoal-stripped FBS (CSFBS), 1%
Antibiotic/Antimycotic. Isolation of androgen independent
cells was conducted by passaging LNCaP-104S cells in
DMEM/10% CSFBS, supplemented with or without
5 μM Bicalutamide (Fluka) (Casodex, CDX) for 3 weeks
(detail treatment method is in the Additional file 12
supplemental method section). Cells were harvested for pro-
tein or RNA extraction at 7 and 21 days post treatment.
RNA extraction and cDNA synthesis
Total RNA was extracted from untreated and treated
cells using the Cell-to-Cts kit (System Biosciences) ac-
cording to the manufacturer’s instructions. Total RNA
was converted to cDNA utilizing the QuantiMir RT Kit
(System Biosciences) according to the manufacturer’s
instructions. Briefly, small RNAs were first tagged with
polyA-tails; oligo-dT primers were annealed next, and
converted to cDNA by reverse transcription.
Quantitative real-time PCR
Expression of mature miRNAs in untreated and treated
LNCaP cells was determined by quantitative real-time
PCR (qRT-PCR) using the miRNome microRNA Profiling
Kit (System Biosciences) and cDNAs according to the man-
ufacturer’s instruction. The kit provides specific primers for
1,113 mature miRNAs and 3 internal control snRNAs.
MiRNA IDs listed in the text are based on Sanger miRBase
identifiers. Primers were designed to maintain uniform
amplification efficiencies. qRT-PCR was conducted using
the Applied Biosystems 7900HT thermal cycler and dataanalyzed using and SDS2.3 software. DNA concentrations
were reported through SYBR Green fluorescence and nor-
malized to that of the passive reference dye, ROX.
Statistical analysis of miRNA expression
Ct values generated by the SDS2.3 software were normalized
according to the average Ct values of the three internal
controls provided with the miRNome Profiler kit using
qbasePLUS software (Biogazelle). In order to ensure the
integrity of the ΔCt values, we utilized the Genorm
software (Biogazelle) to identify 7 additional miRNAs
displaying stable expressions between samples. The Ct
values of all miRNAs were then normalized to these 10
controls. The relative expression values were then gen-
erated using qbasePLUS software and used in additional
analysis (detail explanation is in the Additional file 12
supplemental method section). The Ct values were used
to derive ΔΔCt values using the miRNome analysis soft-
ware (SBI). Candidate miRNAs with higher fold change
values in each treatment conditions were determined by
z score calculation as described in the Additional file 12
supplemental method section.
Clustering was performed using log2 transformed average
ΔΔCt values and the Cluster 3.0 software (Michiel de Hoon,
Univ of Tokyo, based on Eisen Lab Cluster software). Hier-
archical clustering of the miRNAs was based on the average
linkage of the Pearson’s correlation values. The relative ex-
pression values were Log2 transformed and used for evalu-
ation of differences among groups of treated and untreated
cells by performing a Welch t-test using MultExperiment
Viewer (MEV) software. Results of the t-test were displayed
in Volcano plots using -log10 P values of the log2 trans-
formed values. The K-median clustering of the normalized
values were performed using MEV software.
Next, identification of target mRNAs, creation of
miRNA-protein networks, and identification of altered
cellular processes were conducted using the IPA soft-
ware (Ingenuity Systems). The ΔΔCt values were used
for a core analysis by selecting all tissue and cell types
and using a stringent filter and generating direct rela-
tionships only. From the core analysis, mRNA targets
were identified for each sample and these mRNAs were
used to generate the Venn diagrams using online tool
(Venny: http://bioinfogp.cnb.csic.es/tools/venny/index.html).
The miRNA-protein network generated by the core analysis
was overlayed with different cancer types and members of
the network that displayed alterations in those cancers were
identified using the Interactive Pathway Analysis (IPA)
software (Ingenuity Systems). All connections made in
the networks are based on previously published results.
Western blotting
Cells harvested at different time points were lysed and
total protein extracts were used for western blotting
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MA), PSA (Santa Cruz Biotechnology, Dallas, TX), Cbl
(C-15) (Santa Cruz Biotechnology, Dallas, TX), TRAF6
(Millipore, Temecula, CA), p27Kip1 (C-19) (Santa Cruz,
Biotechnology), IRAK1 (F-4) (Santa Cruz, Biotechnology),
ZFAND1 (A-14) (Santa Cruz Biotechnology), FGD4
(Epitomics, Burlingame, CA), ABHD3 (Biorbyt, Cambrige,
UK), DOK4 (C-16) (Santa Cruz Biotechnology), EGFR
(1005) (Santa Cruz Biotechnology), VEGFA (A-20) (Santa
Cruz Biotechnology), α-tubulin (Cell Signaling, Danvers,
MA), GAPDH (Sigma-Aldrich, St. Louis, MO). Total ex-
tracts (30–50 μg) were directly mixed with Lammeli sam-
ple buffer and separated on SDS-PAGE. Immunoblotting
was performed using appropriate primary and horseradish
peroxidase conjugated respective secondary antibodies.
Positive signals were detected using a chemiluminiscence
ECL kit (Pierce, Rockford, IL).Additional files
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